Ewing sarcoma: Historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future

Current Opinion in Oncology

Volumn 20, Issue 4, 2008, Pages 412-418

  Ludwig, Joseph A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; Cancer; Ewing's sarcoma; IGF 1R; Molecular markers; Phase II trials; Prognosis; Sarcoma; Staging; Targeted therapy

Indexed keywords

BIOLOGICAL MARKER; CAMPTOTHECIN; CD99 ANTIGEN; CP 751871; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; IMC A12; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NVP AEW 541; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; R 1507; RNA BINDING PROTEIN EWS; SCH 717454; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TEMOZOLOMIDE; TOPOTECAN; TRABECTEDIN; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG TARGETING; EWING SARCOMA; HUMAN; INOPERABLE CANCER; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; TUMOR SUPPRESSOR GENE; BONE TUMOR; PATHOLOGY;

BONE NEOPLASMS; HUMANS; NEOPLASM STAGING; SARCOMA, EWING'S;

EID: 47249160783     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328303ba1d     Document Type: Review

References (55)

1. Ewing J. Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. CA Cancer J Clin 1972; 22:95-98.
2. Angervall L, Enzinger FM. Extraskeletal neoplasm resembling Ewing's sarcoma. Cancer 1975; 36:240-251.
3. Askin FB, Rosai J, Sibley RK, et al. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 1979; 43:2438-2451.
4. Jaffe R, Santamaria M, Yunis EJ, et al. The neuroectodermal tumor of bone. Am J Surg Pathol 1984; 8:885-898.
5. de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000; 18:204-213.
6. Herzog CE. Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol 2005; 27:215-218.
7. Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer 1993; 53:371-376.
8. Desmaze C, Zucman J, Delattre O, et al. Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumors. Genes Chromosomes Cancer 1992; 5:30-34.
9. Zucman J, Delattre O, Desmaze C, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer 1992; 5:271-277.
10. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359:162-165.
11. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331:294-299.
12. Azuma M, Embree LJ, Sabaawy H, Hickstein DD. Ewing sarcoma protein ewsr1 maintains mitotic integrity and proneural cell survival in the zebrafish embryo. PLoS ONE 2007; 2:e979.
13. May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11; 22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993; 90:5752-5756.
14. Honoki K, Stojanovski E, McEvoy M, et al. Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis. Cancer 2007; 110: 1351-1360. A meta-analysis of the prognostic significance of p16 INK4a for Ewing's sarcoma.
15. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341:342-352.
16. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18:3108-3114.
17. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002; 94:561-569.
18. de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16:1248-1255.
19. Lin PP, Brody RI, Hamelin AC, et al. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res 1999; 59:1428-1432.
20. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996; 14:1245-1251.
21. Chow E, Merchant TE, Pappo A, et al. Cutaneous and subcutaneous Ewing's sarcoma: an indolent disease. Int J Radiat Oncol Biol Phys 2000; 46:433-438.
22. Sutow WW, Sullivan MP. Cyclophosphamide therapy in children with Ewing's sarcoma. Cancer Chemother Rep 1962; 23:55-60.
23. Pinkel D. Cyclophosphamide in children with cancer. Cancer 1962; 15:42-49.
24. Rosen G, Wollner N, Tan C, et al. Proceedings: disease-free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer 1974; 33:384-393.
25. Hayes FA, Thompson EI, Meyer WH, et al. Therapy for localized Ewing's sarcoma of bone. J Clin Oncol 1989; 7:208-213.
26. Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988; 61:23-32.
27. Razek A, Perez CA, Tefft M, et al. Intergroup Ewing's Sarcoma Study: local control related to radiation dose, volume, and site of primary lesion in Ewing's sarcoma. Cancer 1980; 46:516-521.
28. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694-701.
29. Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000; 36:87-94.
30. Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group. Blood 2007; 109:46-51.
31. Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide - a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004; 22:2873-2876.
32. Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric Oncology Group phase II study. J Clin Oncol 2001; 19:3463-3469.
33. Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006; 47:795-800.
34. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004; 10:840-848.
35. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007; 48:132-139.
36. Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2008; 50:254-258. Despite the fact that c-kit is often expressed by Ewing's sarcoma cells, imatinib does not appear to be effective when used alone as only one patient responded out of 24 treated.
37. Baserga R. Targeting the IGF-1 receptor: from rags to riches. Eur J Cancer 2004; 40:2013-2015.
38. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997; 272:30822-30827.
39. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996; 56:4570-4574.
40. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004; 24:7275-7283.
41. Benini S, Manara MC, Cerisano V, et al. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer 2004; 108:358-366.
42. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway - therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007; 4:591-602.
43. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor - specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007; 13:1322-1330. The above article provides an excellent summary of the role of IGF-1R in Ewing's sarcoma pathogenesis and describes preclinical evaluation of a novel small-molecular IGF-1R inhibitor.
44. Scotlandi K, Baldini N, Cerisano V, et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 2000; 60:5134-5142.
45. Cerisano V, Aalto Y, Perdichizzi S, et al. Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 2004; 23:5664-5674.
46. May WA, Lessnick SL, Braun BS, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993; 13:7393-7398.
47. Toretsky JA, Connell Y, Neckers L, Bhat NK. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 1997; 31:9-16.
48. Tanaka K, Iwakuma T, Harimaya K, et al. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997; 99:239-247.
49. Lambert G, Bertrand JR, Fattal E, et al. EWS FLI-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun 2000; 279:401-406.
50. Asami S, Chin M, Shichino H, et al. Treatment of Ewing's sarcoma using an antisense oligodeoxynucleotide to regulate the cell cycle. Biol Pharm Bull 2008; 31:391-394. The authors report the successful use of antisense oligodeoxynucleotide against a chimeric gene product to induce regression of embyonic stem tumor growth. This type of therapy, or one similar to it, may eventually prove to be effective for treatment of embyonic stem patients.
51. Kovar H, Aryee DN, Jug G, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996; 7:429-437.
52. Zhou Z, Bolontrade MF, Reddy K, et al. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 2007; 13:4867-4873.
53. Schaefer KL, Eisenacher M, Braun Y, et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008; 44:699-709. The above is one of the only studies to use DNA microarrays to characterize which genes or pathways are associated with good-chemotherapy or poor-chemotherapy response in Ewing's sarcoma patients treated on the ongoing EURO-EWING99 protocol. A number of those differentially expressed genes are currently in preclinical evaluation as potential targets of biological therapy.
54. Uren A, Wolf V, Sun YF, et al. Wnt/frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer 2004; 43:243-249.
55. Zwerner JP, Joo J, Warner KL, et al. The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 2007 [Epub ahead of print].